Dasatinib-induced Pulmonary hypertension in acute lymphoblastic leukemia: Case report

Turk Kardiyoloji Dernegi Arsivi

Volumn 43, Issue 1, 2015, Pages 78-81

  Taçoy, Gülten ^a   Çengel, Atiye ^a   Özkurt, Zübeyde Nur ^a   Türkoʇlu, Sedat ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; Dasatinib; Hypertension; pulmonary

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENTS; PYRIMIDINES; THIAZOLES;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CARDIOMEGALY; CASE REPORT; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; FATIGUE; FATIGUE CARDIAC TOXICITY,; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT BUNDLE BRANCH BLOCK; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE PRESSURE; HEART SIZE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HOSPITAL ADMISSION; HUMAN; LUNG ARTERY PRESSURE; MAINTENANCE THERAPY; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT DEPARTMENT; PHYSICAL EXAMINATION; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SYSTOLIC HEART MURMUR; TACHYCARDIA; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; CHEMICALLY INDUCED; HUMANS; HYPERTENSION, PULMONARY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC AGENTS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; THIAZOLES;

EID: 84931840668     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2015.41763     Document Type: Article

References (12)

1. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
2. Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14.
3. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-801.
4. Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol 2005;84:792-5.
5. Rix U, Hantschel O, Dümberger G, Remsing Rix LL, Planyavsky M, Fembach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63.
6. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37.
7. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001;120:801-8.
8. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967-8.
9. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861-4.
10. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30.
11. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, lowdose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 2012;36:e4-6.
12. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011;38:218-20.